Literature DB >> 36163429

The 5-year longitudinal diagnostic profile and health services utilization of patients treated with electroconvulsive therapy in Quebec: a population-based study.

Simon Lafrenière1,2, Fatemeh Gholi-Zadeh-Kharrat3,4, Caroline Sirois4,5,6, Victoria Massamba4, Louis Rochette4, Camille Brousseau-Paradis7, Simon Patry8,9, Christian Gagné10, Morgane Lemasson7, Geneviève Gariépy11,12, Chantal Mérette8,13, Elham Rahme14, Alain Lesage7,12.   

Abstract

PURPOSE: Electroconvulsive therapy (ECT) is effective for treating several psychiatric disorders. However, only a minority of patients are treated with ECT. It is of primary importance to characterize their profile for epidemiological purposes and to inform clinical practice. We aimed to characterize the longitudinal profile of psychopathology and services utilization of patients first treated with ECT.
METHODS: We conducted a population-based comparative study using data from a national administrative database in Quebec. Patients who received a first ECT between 2002 and 2016 were compared to controls who were hospitalized in psychiatry but did not receive ECT. We performed descriptive analyses to compare psychiatric diagnoses, domains of psychopathology (internalizing, externalizing and thought/psychotic disorders), medical services and medication use in the 5 years prior to the ECT or hospitalization.
RESULTS: 5 080 ECT patients were compared with 179 594 controls. Depressive, anxiety, bipolar and psychotic disorders were more frequent in the ECT group. 96.2% of ECT patients had been diagnosed with depression and 53.8% with a primary psychotic disorder. In the ECT group, 1.0% had been diagnosed exclusively with depression and 47.0% had disorders from that belong to all three domains of psychopathology. Having both internalizing and thought/psychotic disorders was associated with an increased likelihood of receiving ECT vs having internalizing disorders alone (unadjusted OR = 2.93; 95% CI = 2.63, 3.26). All indicators of mental health services utilization showed higher use among ECT patients.
CONCLUSION: Our results provide robust evidence of complex longitudinal psychopathology and extensive services utilization among ECT patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Comorbidities; Depression; Epidemiology; HiTOP; Observational studies; Schizophrenia

Year:  2022        PMID: 36163429     DOI: 10.1007/s00127-022-02369-w

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.519


  21 in total

1.  Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of electroconvulsive therapy.

Authors:  Alan Weiss; Salam Hussain; Bradley Ng; Shanthi Sarma; John Tiller; Susan Waite; Colleen Loo
Journal:  Aust N Z J Psychiatry       Date:  2019-04-10       Impact factor: 5.744

2.  Contemporary use and practice of electroconvulsive therapy worldwide.

Authors:  Kari Ann Leiknes; Lindy Jarosh-von Schweder; Bjørg Høie
Journal:  Brain Behav       Date:  2012-05       Impact factor: 2.708

Review 3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Authors:  Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care.

Authors:  Raymond W Lam; Diane McIntosh; JianLi Wang; Murray W Enns; Theo Kolivakis; Erin E Michalak; Jitender Sareen; Wei-Yi Song; Sidney H Kennedy; Glenda M MacQueen; Roumen V Milev; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

5.  Using administrative health data to estimate prevalence and mortality rates of alcohol and other substance-related disorders for surveillance purposes.

Authors:  Christophe Huỳnh; Steve Kisely; Louis Rochette; Éric Pelletier; Didier Jutras-Aswad; Alexandre Larocque; Marie-Josée Fleury; Alain Lesage
Journal:  Drug Alcohol Rev       Date:  2021-01-11

Review 6.  Difficult-to-treat depression: the role of contexts and comorbidities.

Authors:  Nancy K Grote; Ellen Frank
Journal:  Biol Psychiatry       Date:  2003-04-15       Impact factor: 13.382

7.  Electroconvulsive Therapy Practice in the Province of Quebec: Linked Health Administrative Data Study from 1996 to 2013.

Authors:  Morgane Lemasson; Julie Haesebaert; Louis Rochette; Eric Pelletier; Alain Lesage; Simon Patry
Journal:  Can J Psychiatry       Date:  2017-10-25       Impact factor: 4.356

8.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

Review 9.  Pharmacological approaches to the challenge of treatment-resistant depression.

Authors:  Dawn F Ionescu; Jerrold F Rosenbaum; Jonathan E Alpert
Journal:  Dialogues Clin Neurosci       Date:  2015-06       Impact factor: 5.986

10.  Utilization of Health Care Services by Patients With Cluster B Personality Disorders or Schizophrenia.

Authors:  Lionel Cailhol; Éric Pelletier; Louis Rochette; Suzane Renaud; Marion Koch; Pierre David; Evens Villeneuve; Carlotta Lunghi; Alain Lesage
Journal:  Psychiatr Serv       Date:  2021-07-20       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.